1
(Expanding horizons in metastatic prostate cancer treatment. Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2011.67-c1) 2 -in which we focus on the current and emerging therapies for bone metastases in patients with castration-resistant prostate cancer (CRPC). We also thank them for bringing to our attention several errors in Tables 1 and 2 . These have been corrected for the HTML and PDF versions of the article. 3 In our Review, we discussed the Medical Research Council (MRC) PR05 trial, which recruited men with prostate cancer and metastatic bone disease (MBD) who had started or responded to long-term hormone therapy. 4 The long-term survival data from the final analysis included data from 278 patients (89%) of the original 311 men recruited to the study, and 258 deaths (93%) were reported. In the analysis by Dearnaley et al., 4 a total of 31 patients (10%) were excluded because they were not registered in England and Wales and a further two patients (1%) were not identified by the UK National Health Service Information Centre. 5 will ascertain if the more-potent bisphosphonate, zoledronic acid, is also of benefit to men starting long-term hormone therapy.
The superior efficacy of the fully human monoclonal antibody, denosumab, compared with zoledronic acid was given credence in our section titled: The new option: RANK-RANKL inhibition. 1 The recent findings of the Amgen funded trial (NCT00104650) in men with CRPC and MBD, 6 in which patients were randomly assigned to receive denosumab (n = 951) or zoledronic acid (n = 950), consolidates our proposal of this new option for the treatment of men with CRPC and MBD. The median time to first on-study skeletal-related event (SRE) reported was 20.7 months for denosumab compared with 17.1 months for zoledronic acid. The only notable difference in the frequency of adverse events was hypocalcemia, which occurred in 13% of patients treated with denosumab and 6% of patients treated with zoledronic acid. 6 A second trial funded by Amgen (NCT00089674) 7 reported that denosumab improved bone mineral density and decreased vertebral fracture rate in patients with non-metastatic cancer receiving androgen deprivation therapy. These exciting findings provide an important adjunct to our review 1 and give further encouragement to health-care providers for the successful treatment of patients with metastatic prostate cancer. 
